UNITUXIN

This brand name is authorized in United States. It is also authorized in Canada, Estonia, Japan, Lithuania.

Active ingredients

The drug UNITUXIN contains one active pharmaceutical ingredient (API):

1	Dinutuximab UNII 7SQY4ZUD30 - DINUTUXIMAB
	Dinutuximab is a monoclonal chimeric antibody composed of murine variable heavy and light chain regions and the human constant region for the heavy chain IgG1 and light chain kappa. Dinutuximab reacts specifically with the ganglioside GD2, which is highly expressed on the surface of neuroblastoma cells and minimally expressed on the surface of normal human neurons, peripheral pain fibres, and skin melanocytes.
	Read more about Dinutuximab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
UNITUXIN Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FX06	Dinutuximab beta	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02483076
EE	Ravimiamet	1693953
JP	医薬品医療機器総合機構	4291457A1025
LT	Valstybinė vaistų kontrolės tarnyba	1077858
US	FDA, National Drug Code	66302-014